Tezepelumab (Tezspire) for Nasal Polyps
Tezepelumab (Tezspire) for Nasal Polyps
October 26, 2026 (Issue: 1766)
The FDA has approved tezepelumab (Tezspire – Amgen/AstraZeneca), a subcutaneously administered thymic
stromal lymphopoietin (TSLP) blocker, for add-on
maintenance treatment of inadequately controlled chronic
rhinosinusitis with nasal polyps...more
- Tezepelumab (Tezspire) for severe asthma. Med Lett Drugs Ther 2022; 64:25.
- MA Rank et al. The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 2023; 151:386. doi:10.1016/j.jaci.2022.10.026
- A Safia et al. Optimizing biologic treatment selection in chronic rhinosinusitis with nasal polyps: a network meta-analysis of efficacy and safety across 22 RCTs. Pharmaceuticals (Basel) 2025; 18:1455. doi:10.3390/ph18101455
- JC Simmonds et al. Endoscopic sinus surgery for chronic rhinosinusitis: 22-item sino-nasal outcome test 5-year results. Int Forum Allergy Rhinol 2022; 12:257. doi:10.1002/alr.22886
- A Oka et al. Tezepelumab inhibits highly functional truncated thymic stromal lymphopoietin in chronic rhinosinusitis. J Allergy Clin Immunol 2025; 156:463. doi:10.1016/j.jaci.2025.02.031
- BJ Lipworth et al. Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps. N Engl J Med 2025; 392:1178. doi:10.1056/nejmoa2414482
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Tezepelumab (Tezspire) for Nasal Polyps
Article code: 1766b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
